Articles and Insights About Wearables for Clinical Trials

VivoSense recently published an American Society of Clinical Oncology's JCO Clinical Cancer Informatics review article, Measuring What Is Meaningful in Cancer Cachexia Clinical Trials: A Path Forward With Digital Measures of Real-World Physical Behavior.

VivoSense Research Scientist Shelby Bachman, PhD, presented the poster, Real-world physical behavior is associated with aerobic fitness, but not patient-reported outcomes, in cancer survivors, at the October 22, 2023, Banff 9th Annual PROMIS International Conference, a multi-disciplinary forum for learning about the use of patient-reported outcome measures in clinical care and research. Shelby’s poster presentation summarized VivoSense’s recent work examining the clinical utility of real-world digital measures in oncology. Here's a quick snapshot of the poster content.

VivoSense published a Karger review article, The Case for the Patient-Centric Development of Novel Digital Sleep Assessment Tools in Major Depressive Disorder.

Research scientist Shelby Bachman, PhD, spoke at the Roche Digital Biomarkers in Clinical Trials Summit on the prospects for wearable sensors for measuring health-related quality of life in cancer survivors.

VivoSense^®3.6 update is live and ready! We are committed to continually expanding its capabilities to provide visualization and analysis for data from wearable sensors in clinical research.

In collaboration with researchers at the University of Massachusetts Amherst, VivoSense published a new review paper in the Journal of Alzheimer’s Disease. The review summarizes how measures of real-world physical behavior, captured with digital health technologies, can contribute to more holistic assessment of functional independence in Alzheimer’s disease clinical research.

On June 7th, 2023, Robert Wright, PhD, Senior Research Scientist at VivoSense, and Jana Von Hehn, PhD, CSO at Rett Syndrome Research Trust, presented at the Digital Health Innovation Summit, a forum to learn from the best about top trends in the industry. Their presentation, Developing Patient-Centric Real-World Digital Clinical Measures for Rett Syndrome, summarized years of collaborative work implementing digital health technologies in complex research programs.

We are thrilled to announce Colin Bower as our new Chief Executive Officer and a member of our Board of Directors. Bower will succeed Dudley Tabakin, who will work closely with Bower to achieve a seamless transition. Tabakin will continue with VivoSense in his new capacity as Chief Product Officer.

We all know it's important to choose "measures that matter" when selecting and developing digital measures for evidence generation in clinical trials, but how do we put these good intentions into action? How do we lay solid, patient-centric foundations, whether that means designing a protocol, building an integrated evidence plan, or qualifying a novel evidence tool?

DATAcc announced the release of the Analytical Validation Library on May 23, 2023! Kate Lyden, Ph.D. and VivoSense CSO collaborated with other industry leaders to show ‘what good looks like’ regarding high-quality analytical validation. As new DHTs come online, industry-wide standards must be developed in tandem to ensure their ability to measure, detect or predict a clinical state.